Hirschfield, Gideon M.
University Health Network · Toronto General Hospital
95 papers on CoChatORCID 0000-0002-6736-2255
Most cited papers
- Verified
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation
Biomarkers in Disease MechanismsAdipokines, Inflammation, and Metabolic Diseases
Cited by 3,436
- Verified
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine
Lipoproteins and Cardiovascular HealthInflammatory Biomarkers in Disease Prognosis
Cited by 2,953
- Verified
The gut microbiota and host health: a new clinical frontier
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., et al. (2016) · Gut
Gut microbiota and healthProbiotics and Fermented Foods
Cited by 2,302
- Verified
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 1,480
- Verified
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 1,131
- Verified
Targeting C-reactive protein for the treatment of cardiovascular disease.
Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., et al. (2006) · Nature
Biomarkers in Disease MechanismsComplement system in diseases
Cited by 672
- Verified
Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine
Liver Diseases and ImmunityGenetic Associations and Epidemiology
Cited by 594
- Verified
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 576
- Verified
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
Mózes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N. A., Trauner, M., Boursier, J., Fournier, C., Staufer, K., Stauber, R. E., Bugianesi, E., et al. (2022) · Gut
Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation
Cited by 556
- Verified
Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue
Boberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology
Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases
Cited by 555
- Verified
Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis
Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology
Liver Diseases and ImmunityInflammatory Bowel Disease
Cited by 533
- Verified
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study
Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 498
- Verified
Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 441
- Verified
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis
Liu, X., Invernizzi, P., Lu, Y., Kosoy, R., Lu, Y., Bianchi, I., Podda, M., Xu, C., Xie, G., Macciardi, F., et al. (2010) · Nature Genetics
Liver Diseases and ImmunityGenetic Associations and Epidemiology
Cited by 398
- Verified
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
The UK-PSCSC Consortium, Liu, J. Z., The International IBD Genetics Consortium, The International PSC Study Group, Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., Andreassen, O. A., et al. (2013) · Nature Genetics
Liver Diseases and ImmunityGenetic Associations and Epidemiology
Cited by 391
- Verified
Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis
Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 372
- Verified
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 362
- Verified
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease
The UK-PSC Consortium, Ji, S.-G., The International IBD Genetics Consortium, The International PSC Study Group, Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., Kumasaka, N., et al. (2017) · Nature Genetics
Liver Diseases and ImmunityGenetic Associations and Epidemiology
Cited by 357
- Verified
The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis
Carbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 354
- Verified
The immunobiology and pathophysiology of primary biliary cirrhosis
Hirschfield, G. M., & Gershwin, M. E. (2013) · Annual Review of Pathology: Mechanisms of Disease
Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases
Cited by 315
- Verified
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 308
- Verified
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology
Liver Diseases and ImmunityInflammatory Bowel Disease
Cited by 297
- Verified
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis
Harms, M. H., van Buuren, H. R., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Hirschfield, G. M., Parés, A., Floreani, A., Mayo, M. J., et al. (2019) · Journal of Hepatology
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 289
- Verified
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology
Liver Diseases and ImmunityLiver physiology and pathology
Cited by 287
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free